RAMES study: is there really a role for VEGF inhibition in mesothelioma? - Authors' reply
- PMID: 34856143
- DOI: 10.1016/S1470-2045(21)00666-5
RAMES study: is there really a role for VEGF inhibition in mesothelioma? - Authors' reply
Conflict of interest statement
PAZ reports personal fees for advisory roles, speaker engagements, and travel and accommodation expenses from Merck Sharp and Dohme, Astellas, Janssen, Sanofi, Ipsen, Pfizer, Novartis, Bristol Myers Squibb, Amgen, AstraZeneca, Roche, and Bayer, outside the submitted work. GLC reports personal fees for speaker engagements from Merck Sharp and Dohme, Astellas, Novocure, Zai Lab, AstraZeneca, Bristol Myers Squibb, Medarex, and Bayer; advisory roles from Merck Sharp and Dohme, Astellas, Novocure, and Zai Lab; and travel and accommodation expenses from Merck Sharp and Dohme, Astellas, and Novocure, outside the submitted work. CP declares no competing interests.
Comment in
-
RAMES study: is there really a role for VEGF inhibition in mesothelioma?Lancet Oncol. 2021 Dec;22(12):e532. doi: 10.1016/S1470-2045(21)00640-9. Lancet Oncol. 2021. PMID: 34856142 No abstract available.
Comment on
-
Gemcitabine with or without ramucirumab as second-line treatment for malignant pleural mesothelioma (RAMES): a randomised, double-blind, placebo-controlled, phase 2 trial.Lancet Oncol. 2021 Oct;22(10):1438-1447. doi: 10.1016/S1470-2045(21)00404-6. Epub 2021 Sep 6. Lancet Oncol. 2021. PMID: 34499874 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical